obi - good time to sell my friend - currently at 2.02 - How many shares can I buy from you?
A good question - implications? Maybe this question could be redirected to Curis mgt to see if a) they respond b) see that investors are VERY interested in their stock c) a contact within Curis is identified - just a thought. probably lame
he is simply a player who attempts to get in low and ride for a few cents up. No value in his posts to me. You can take it if you want or just put him on "ignore" list.
Thanks for the updates and welcome back to Bentbasin. Did you buy back any? or were you continuing to hold?
I have not been able to take a peek at the talk yet. hopefully it is recorded and available at curis. Getting ph2 going by Dec "SHOULD" be accomplished by them. Hopefully he keeps that one up. There are others that are building momentum in the same or similar indications and we need to get 907 out there soon.
The arubindo molecules are just that for now "molecules" with promise as any others. There are several (both small and large moledule-antibody) that are now immuno-oncology focussed but most have met with side effects. We shall see but my hope is that 907 gets into the market soon. Good luck.
He used the phrase "registration enabled" to describe the phase. I am assuming ASH has accepted its abstract in which case it will be published on November 4th; best case scenario is that phase 2 is a pivotal trial and next year trial shows positive results for patients with transformed follicular DLBCL. If shorts are betting trial will not start in December, all power to them but at least yesterday's presentation will make them sweat it. ASH conference should generate some buzz.
"They are in discussion with FDA regarding making it a registration directed trial.".....been said for 6 months at least. But I do appreciate what you add here as always Tar. As the old saying goes if you're going to talk the talk, need to walk the walk...Ali hasn't done it to date. He constantly commits one of the oldest sins in business; over promises, under delivers. Ok had my moment(s) to vent. Back to waiting......hoping.
I'll keep this short and sweet...Google "PennyStock101' signup for their free newsletter and get their next trade alert. Come back and thank me tomorrow!
Just heard Fattaey's presentation. Definitely sticking to deadline of filing Ph2 by December; said they "have figured out why 907 is effective in treating refractory/relapsed DKBCL patients" based on their genetic profiles. Said they are in discussion with FDA regarding making it a registration directed trial. Said more would be coming at ASH on this. Really talked up Aurigene molecules, one is now identified as CA-107. Interested in knowing what others thought of presentation; I was impressed with his authoritative tone. Hopefully this is the lowest the stock price gets.
Sentiment: Strong Buy
Well thanks for the clarification and now I see why we are down so much for soooo looooong.
Ali bought in at 1.61 or something correct in Aug 2014 - that's when I bought. So can anyone tell us what he said or will say today?
The unfortunate thing is, I really thought this guy was the answer but he's used all his goodwill capital with consistently missed goals and now has one heck of a hole to climb from. jmo
Not sure why people feel PII 907 is starting this year. As anyone knows, Ali promised 5 things in January's presentation and 4 of them are guaranteed not to happen. Just go to the clinicaltrials.gov site and look at the completion date for PI for 907. Need I say more?
At tomorrow's presentation, if Fattaey does not announce that Curis has pushed back the ph2 to next year, then I am taking Curis at its word, i.e. that ph2 will start in the fourth quarter, probably December after ASH.